SV112 Delivery™ Lipid Nanoparticle R&D

SunVax is a pioneering biotechnology company located in the Greater Boston area, specializing in the development of advanced lipid nanoparticle (LNP) delivery systems and self-amplifying mRNA (samRNA) platforms. Leveraging a proprietary library of over one million molecular structures, SunVax has synthesized and screened more than 60,000 ionizable lipids through high-throughput methods. 

To accelerate progress in the mRNA research community, SunVax launched a series of ready-to-use LNP kits in research use only for proof-of-concept and screening mRNA constructs in vitro/in vivo.

SV112 Delivery™ Instant LNP Kit PLUS (Capable in vivo for RUO)

Key features include:

• Simple and rapid use —just mix your mRNA with the formulation/lipid mixture for immediate in vitro application or concentrate for in vivo use.
• High encapsulation efficiency (EE>90%), consistent particle size (~100nm), and robust transfection performance. 
• Ideal for labs and researchers lacking specialized LNP formulation expertise or equipment.
• Excellent for proof-of-concept studies, mRNA screening, and early-stage research.

These kits embody an “instant coffee”—like convenience—streamlining LNP-mRNA delivery for researchers.

For pipeline development or more complicated applications, we strongly recommend contacting SunVax (SunVax_Customer@sunvaxmrna.com) to access optimized formulations prepared by standard procedures.

Characterizations of generic LNP formulations by SV112Delivery™ and SV112Delivery™ Plus kits

Figure 1. The Characterizations of LNP SV112Delivery™ and SV112Delivery™ Plus Kits. The kits exhibit consistently high encapsulation efficiency (>90%) (A), generate nanoparticles with a uniform average size of approximately 110 nm (B), and maintain a low polydispersity index (PDI)(C). 

Figure 2. Stability of LNP formulations prepared with the SV112Delivery™ kits. Formulation mixtures underwent four freeze–thaw cycles prior to complexing with eGFP mRNA in formulation buffer. Shown are encapsulation efficiency (A), nanoparticle size (B), polydispersity index (PDI) (C), and transfection efficiency in HEK 293 cells (D).

Transfection efficiency of LNP-mRNA in vitro and in vivo using SV112Delivery™ and SV112Delivery™ Plus kits

Figure 3. The SV112Delivery™ and SV112Delivery™ Plus kits demonstrated strong transfection efficacy in both in vitro and in vivo models. (A) In vitro transfection efficacy: HEK 293 cells were transfected with mRNA encoding eGFP using SV112Delivery™ kits. Shown are FACS plots of GFP (X-axis) versus Live/Dead staining (Y-axis) one day post-transfection. Data are presented as mean ± standard deviation (n=3).  (B) In vivo transfection efficacy: Balb/c mice were intravenously injected with LNP-mRNA encoding Luciferase (10 µg) formulated with SV112Delivery™ Plus kits (left) or PBS (right). Shown are IVIS images at 6 hours (upper) and 24 (bottom) hours post-injection.

Store Temperature

Formulation Mixture: -80 °C

Formulation Buffer: Room Temperature